<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>17(R),18(S)-epoxyeicosatetraenoic acid [17(R),18(S)-EETeTr], a <z:chebi fb="0" ids="38559">cytochrome P450</z:chebi> epoxygenase metabolite of eicosapentaenoic acid (<z:chebi fb="113" ids="28364">EPA</z:chebi>), exerts negative chronotropic effects and protects neonatal rat cardiomyocytes against Ca(2+)-overload with EC(50) ≈ 1-2 nM </plain></SENT>
<SENT sid="1" pm="."><plain>Structure-activity studies revealed that a cis-Δ(11,12)- or Δ(14,15)-<z:chebi fb="1" ids="33641">olefin</z:chebi> and a 17(R),18(S)-<z:chebi fb="0" ids="32955">epoxide</z:chebi> are minimal structural elements for antiarrhythmic activity whereas <z:chebi fb="68" ids="48706">antagonist</z:chebi> activity was often associated with the combination of a Δ(14,15)-<z:chebi fb="1" ids="33641">olefin</z:chebi> and a 17(S),18(R)-<z:chebi fb="0" ids="32955">epoxide</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Compared with natural material, the <z:chebi fb="4" ids="48705">agonist</z:chebi> and <z:chebi fb="68" ids="48706">antagonist</z:chebi> analogues are chemically and metabolically more robust and several show promise as templates for future development of clinical candidates </plain></SENT>
</text></document>